COVID19

/ Treatment Clinic

COVID-19 Treatment Clinic

Spectrum Health currently offers treatments for confirmed COVID-19 infection. Based on current evidence, oral Paxlovid and intravenous Remdesivir are first-line treatments, while oral Molnupiravir is a second-line treatment. Both oral medications must be started within five days of COVID-19 symptoms onset, while Remdesivir, an intravenous medication, must be given within seven days of symptom onset.

If you have symptoms and test positive for COVID-19, you may either:

Talk to your primary care provider,

or

Call the Spectrum Health Community Response COVID-19 Treatment Clinic.*A virtual visit will be scheduled with a provider who will review your medical history and current medication list to determine eligibility and appropriate treatment.

*The decision for treatment is impacted by multiple factors including, but not limited to, your general medical health, duration of symptoms and medications you are currently taking.

Spectrum Health Community Response 616.391.0351arrow icon

Frequently asked questions

How do I know which treatment option is best for me?
close icon

A health care provider will determine if you are eligible for COVID-19 treatment and which mediation is most appropriate for you based on the U.S. Food and Drug Administration Emergency Use Authorization, Michigan Department of Health and Human Services guidelines, and your medical history.

If I receive an antiviral medication by mouth or intravenously, can I still get the COVID-19 vaccine?
close icon

Yes, you can get the COVID-19 vaccine, and we encourage you to get vaccinated. When receiving COVID-19 treatment, it is recommended to wait two weeks from initial COVID-19 symptom onset before getting vaccinated or boosted.

Does my quarantine duration change after I receive COVID-19 treatment?
close icon

No; your quarantine time will remain the same. Despite the anticipated improvement in your symptoms, you will still be contagious. Please continue isolating, wearing a mask and practicing good handwashing.

COVID-19 treatments under Emergency Use Authorization granted by the U.S. Food and Drug Administration:

  • PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to[1]moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS[1]CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death; and
  • The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID[1]19 pandemic under Section 564(b)(1) of the Act,21 U.S.C. § 360bbb[1]3(b)(1), unless the declaration is terminated or authorization revoked sooner
  • LAGEVRIO (Molnupiravir) has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults who are at high-risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate; and
  • The emergency use of LAGEVRIO is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

Patient stories and news